Recent Acquisition Tidewater Clinical Research was acquired by Eximia Research in August 2024, representing a change in ownership and potential strategic realignment. This creates an opportunity to re-engage as Eximia expands or integrates Tidewater’s operations, especially in women's health and ophthalmology trials in Eastern Virginia.

Regional Focus Operates in Hampton Roads / Eastern Virginia with a specialty in women's health and ophthalmology trials. Leverage local trial access and physician networks to offer sponsor partners targeted patient recruitment and expedited study timelines in a defined geographic market.

SME Footprint Small team size (2-10 employees) combined with access to private practitioners and study-focused staff. This indicates agility but potential capacity constraints; sales strategy can emphasize flexible partnerships, co-fulfillment of study tasks, and scalable subcontracting options.

Industry Positioning Operating within pharmaceutical manufacturing and clinical research with data-driven patient recruitment capabilities. Potential upsell opportunities with sponsors seeking reliable data quality, investigator sites, and streamlined collaboration across sponsors’ trials.

Financial Signals Reported revenue in the range of $10M–$25M suggests a mid-market CRO profile. Engage in conversations about expanded scope deals, multi-study programs, or preferred provider agreements to secure longer-term revenue with sponsor organizations seeking stable partners.